inclusion criteria: * volunteers must meet the following inclusion criteria: type of participants • healthy volunteers. age at the time of signing the informed consent • from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days). paul • male or female. reproductive characteristics * for girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). * for young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). research procedures * written informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial. * volunteers who are able to fulfill protocol requirements (i.e. answer phone calls, fill out a self-observation diary, come to control visits). non-inclusion criteria: * volunteers cannot be included in the study if any of the following criteria are present: sars-cov-2 infection * a case of established covid-19 disease confirmed by pcr and/or elisa in the last 6 months. * history of contacts with confirmed or suspected cases of sars-cov-2 infection within 14 days prior to vaccination. * positive igm or igg to sars-cov-2 detected on screening. * positive pcr test for sars-cov-2 at screening / before vaccination. diseases or medical conditions * serious post-vaccination reaction (temperature above 40 c, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination. * burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.). * guillain-barre syndrome (acute polyradiculitis) in the anamnesis. * the axillary temperature at the time of vaccination is more than 37.0 ° c. * positive blood test for hiv, syphilis, hepatitis b/c. * acute infectious diseases (recovery earl

inclusion criteria: * volunteers must meet the following inclusion criteria: type of participants • healthy volunteers. age at the time of signing the informed consent • from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days). paul • male or female. reproductive characteristics * for girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). * for young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). research procedures * written informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial. * volunteers who are able to fulfill protocol requirements (i.e. answer phone calls, fill out a self-observation diary, come to control visits). non-inclusion criteria: * volunteers cannot be included in the study if any of the following criteria are present: sars-cov-2 infection * a case of established covid-19 disease confirmed by pcr and/or elisa in the last 6 months. * history of contacts with confirmed or suspected cases of sars-cov-2 infection within 14 days prior to vaccination. * positive igm or igg to sars-cov-2 detected on screening. * positive pcr test for sars-cov-2 at screening / before vaccination. diseases or medical conditions * serious post-vaccination reaction (temperature above 40 c, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination. * burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.). * guillain-barre syndrome (acute polyradiculitis) in the anamnesis. * the axillary temperature at the time of vaccination is more than 37.0 ° c. * positive blood test for hiv, syphilis, hepatitis b/c. * acute infectious diseases (recovery earl

inclusion criteria: volunteers must meet the following inclusion criteria: type of participants • healthy volunteers. age at the time of signing the informed consent • from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days). paul • male or female. reproductive characteristics for girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). for young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). research procedures written informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial. volunteers who are able to fulfill protocol requirements (i.e. answer phone calls, fill out a self-observation diary, come to control visits). non-inclusion criteria: volunteers cannot be included in the study if any of the following criteria are present: sars-cov-2 infection a case of established covid-19 disease confirmed by pcr and/or elisa in the last 6 months. history of contacts with confirmed or suspected cases of sars-cov-2 infection within 14 days prior to vaccination. positive igm or igg to sars-cov-2 detected on screening. positive pcr test for sars-cov-2 at screening / before vaccination. diseases or medical conditions serious post-vaccination reaction (temperature above 40 c, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination. burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.). guillain-barre syndrome (acute polyradiculitis) in the anamnesis. the axillary temperature at the time of vaccination is more than 37.0 ° c. positive blood test for hiv, syphilis, hepatitis b/c. acute infectious diseases (recovery earl

inclusion criteria: volunteers must meet the following inclusion criteria: type of participants • healthy volunteers. age at the time of signing the informed consent • from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days). paul • male or female. reproductive characteristics for girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). for young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). research procedures written informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial. volunteers who are able to fulfill protocol requirements (i.e. answer phone calls, fill out a self-observation diary, come to control visits). non-inclusion criteria: volunteers cannot be included in the study if any of the following criteria are present: sars-cov-2 infection a case of established covid-19 disease confirmed by pcr and/or elisa in the last 6 months. history of contacts with confirmed or suspected cases of sars-cov-2 infection within 14 days prior to vaccination. positive igm or igg to sars-cov-2 detected on screening. positive pcr test for sars-cov-2 at screening / before vaccination. diseases or medical conditions serious post-vaccination reaction (temperature above 40 c, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination. burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.). guillain-barre syndrome (acute polyradiculitis) in the anamnesis. the axillary temperature at the time of vaccination is more than 37.0 ° c. positive blood test for hiv, syphilis, hepatitis b/c. acute infectious diseases (recovery earl